JP2003509385A - 両親媒性プロドラッグ - Google Patents

両親媒性プロドラッグ

Info

Publication number
JP2003509385A
JP2003509385A JP2001523037A JP2001523037A JP2003509385A JP 2003509385 A JP2003509385 A JP 2003509385A JP 2001523037 A JP2001523037 A JP 2001523037A JP 2001523037 A JP2001523037 A JP 2001523037A JP 2003509385 A JP2003509385 A JP 2003509385A
Authority
JP
Japan
Prior art keywords
prodrug
etoposide
therapeutic compound
formula
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001523037A
Other languages
English (en)
Japanese (ja)
Inventor
エクウリベ，ヌノキリ・エヌ
ジャコノフ，タチアナ・エイ
プライス，クリストファー・エイチ
Original Assignee
ノベックス・コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノベックス・コーポレイション filed Critical ノベックス・コーポレイション
Publication of JP2003509385A publication Critical patent/JP2003509385A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
JP2001523037A 1999-09-13 2000-09-07 両親媒性プロドラッグ Pending JP2003509385A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15364999P 1999-09-13 1999-09-13
US60/153,649 1999-09-13
US09/474,915 1999-12-31
US09/474,915 US6713454B1 (en) 1999-09-13 1999-12-31 Prodrugs of etoposide and etoposide analogs
PCT/US2000/024520 WO2001019406A2 (en) 1999-09-13 2000-09-07 Amphiphilic prodrugs

Publications (1)

Publication Number Publication Date
JP2003509385A true JP2003509385A (ja) 2003-03-11

Family

ID=26850733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001523037A Pending JP2003509385A (ja) 1999-09-13 2000-09-07 両親媒性プロドラッグ

Country Status (17)

Country Link
US (3) US6713454B1 (US06713454-20040330-C00017.png)
EP (1) EP1212099A2 (US06713454-20040330-C00017.png)
JP (1) JP2003509385A (US06713454-20040330-C00017.png)
KR (1) KR20020059398A (US06713454-20040330-C00017.png)
CN (1) CN1390143A (US06713454-20040330-C00017.png)
AU (1) AU7575600A (US06713454-20040330-C00017.png)
BR (1) BR0013948A (US06713454-20040330-C00017.png)
CA (1) CA2384645A1 (US06713454-20040330-C00017.png)
CZ (1) CZ2002928A3 (US06713454-20040330-C00017.png)
HU (1) HUP0204110A3 (US06713454-20040330-C00017.png)
IL (1) IL148558A0 (US06713454-20040330-C00017.png)
MX (1) MXPA02002712A (US06713454-20040330-C00017.png)
NO (1) NO20021213L (US06713454-20040330-C00017.png)
NZ (1) NZ517681A (US06713454-20040330-C00017.png)
PL (1) PL354261A1 (US06713454-20040330-C00017.png)
RU (1) RU2002109595A (US06713454-20040330-C00017.png)
WO (1) WO2001019406A2 (US06713454-20040330-C00017.png)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517909A (ja) * 2004-01-14 2007-07-05 ギリアード サイエンシーズ， インコーポレイテッド 薬物送達に有用な脂質ベースの分散物
JP2007209748A (ja) * 2006-01-16 2007-08-23 Ito:Kk 創傷治癒用高分子組成物
WO2007135910A1 (ja) * 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha ポドフィロトキシン類の高分子結合体
US8188222B2 (en) 2006-11-08 2012-05-29 Nippon Kayaku Kabushiki Kaisha High molecular weight derivative of nucleic acid antimetabolite
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
US8808749B2 (en) 2009-05-15 2014-08-19 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of bioactive substance having hydroxy group
US8920788B2 (en) 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
US9018323B2 (en) 2010-11-17 2015-04-28 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolic antagonist
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
US9346923B2 (en) 2011-09-11 2016-05-24 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer
US9434822B2 (en) 2004-09-22 2016-09-06 Nippon Kayaku Kabushiki Kaisha Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
WO2001024831A2 (en) 1999-10-04 2001-04-12 Shearwater Corporation Polymer stabilized neuropeptides
AU2001252711A1 (en) * 2000-04-15 2001-10-30 Byung-Wook Jo Aqueous-prodrug compound comprising moiety of paclitxel or derivatives thereof, method of preparing same and pharmaceutical composition comprising same
AU2002249559A1 (en) * 2002-03-28 2003-10-13 Council Of Scientific And Industrial Research 4-beta-1''-`(2''-(substituted benzoyl)anilino! podophyllotoxin analogues useful as anticancer agents
AU2003272068A1 (en) * 2002-10-21 2004-05-04 Ramot At Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
CN100558398C (zh) * 2002-11-26 2009-11-11 拜奥康有限公司 修饰的钠尿化合物、缀合物及其应用
ATE512674T1 (de) * 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
US7140522B2 (en) * 2003-06-26 2006-11-28 Spencer Forrest, Inc. Applicator for hair building solids
CN102895666B (zh) * 2003-12-16 2015-08-19 尼克塔治疗公司 化学改性的小分子
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
SI1859041T2 (sl) * 2005-02-18 2015-04-30 Angiochem Inc. Polipeptidi aprotinina za prenos spojine prek krvno-moĹľganske pregrade
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
AU2006272405B2 (en) 2005-07-15 2013-02-07 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
WO2008041610A1 (fr) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha Mélange d'un dérivé de résorcinol avec un polymère
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2009037707A2 (en) 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
MX355683B (es) * 2008-04-18 2018-04-26 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
AU2009274571A1 (en) * 2008-07-23 2010-01-28 Massachusetts Institute Of Technology Activation of histone deacetylase 1 (HDAC1) protects against DNA damage and increases neuronal survival
MX2011004019A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de etoposido y doxorubicina para entrega de farmacos.
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
BRPI0922689A2 (pt) * 2008-12-05 2018-11-06 Angiochem Inc. conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
MX2011011023A (es) 2009-04-20 2012-01-20 Angiochem Inc Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2.
EP2448965A4 (en) 2009-07-02 2015-02-11 Angiochem Inc MULTIMEPEPTID CONJUGATES AND ITS USES
WO2011053876A1 (en) 2009-10-30 2011-05-05 Massachusetts Institute Of Technology The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
WO2011089214A1 (en) * 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
WO2012048204A2 (en) * 2010-10-08 2012-04-12 Virginia Commonwealth University Prodrugs utilizing a transporter directed uptake mechanism
WO2012149540A1 (en) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
WO2013016193A2 (en) 2011-07-22 2013-01-31 Massachusetts Istitute Of Technology Activators of class i histone deacetlyases (hdacs) and uses thereof
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
EP2852439A1 (en) 2012-05-23 2015-04-01 Stemergie Biotechnology SA Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
US20170007618A1 (en) 2015-06-17 2017-01-12 Massachusetts Institute Of Technology Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
WO2019055236A1 (en) 2017-09-18 2019-03-21 Massachusetts Institute Of Technology PEPTIDES CYCLIN DEPENDENT KINASE 5 INHIBITORS (CDK5)
CN112266409B (zh) * 2020-10-28 2022-05-13 南开大学 依托泊苷自组装纳米纤维多肽、制备方法及应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US611107A (en) * 1898-09-20 Method of forming tobacco into wrappers
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
DE3935016A1 (de) 1989-10-20 1991-04-25 Behringwerke Ag Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5817321A (en) 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
WO1994020453A1 (en) 1993-03-09 1994-09-15 Enzon, Inc. Taxol polyalkylene oxide conjugates of taxol and taxol intermediates
US5547981A (en) 1993-03-09 1996-08-20 Enzon, Inc. Taxol-7-carbazates
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
JPH0782291A (ja) 1993-09-13 1995-03-28 Microbial Chem Res Found 水溶性アンスラサイクリン誘導体
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
AU8052194A (en) 1993-10-20 1995-05-08 Enzon, Inc. 2'- and/or 7- substituted taxoids
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5618528A (en) 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5547027A (en) * 1994-07-14 1996-08-20 Dowell, A Division Of Schlumberger Technology Corporation Low temperature, low rheology synthetic cement
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5756593A (en) 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
EA002400B1 (ru) 1996-03-12 2002-04-25 Пи Джи-Ти Экс Эл Компани, Л.П. Водорастворимые пролекарства противоракового действия
JP4420472B2 (ja) 1996-04-15 2010-02-24 旭化成株式会社 薬物複合体
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
JP2001501601A (ja) 1996-09-12 2001-02-06 メルク エンド カンパニー インコーポレーテッド 前立腺ガンの治療において有用な共役体
EP1001769B1 (en) 1997-06-20 2002-06-19 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1037649B1 (en) 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
JP2002512640A (ja) 1998-03-23 2002-04-23 コンジュケム，インコーポレーテッド 持続性治療薬の局所送達
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
JP2003507438A (ja) 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517909A (ja) * 2004-01-14 2007-07-05 ギリアード サイエンシーズ， インコーポレイテッド 薬物送達に有用な脂質ベースの分散物
US9434822B2 (en) 2004-09-22 2016-09-06 Nippon Kayaku Kabushiki Kaisha Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
JP2007209748A (ja) * 2006-01-16 2007-08-23 Ito:Kk 創傷治癒用高分子組成物
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
US8940332B2 (en) 2006-05-18 2015-01-27 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
WO2007135910A1 (ja) * 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha ポドフィロトキシン類の高分子結合体
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
US8188222B2 (en) 2006-11-08 2012-05-29 Nippon Kayaku Kabushiki Kaisha High molecular weight derivative of nucleic acid antimetabolite
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
USRE46190E1 (en) 2007-09-28 2016-11-01 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
US8920788B2 (en) 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
US8808749B2 (en) 2009-05-15 2014-08-19 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of bioactive substance having hydroxy group
US9018323B2 (en) 2010-11-17 2015-04-28 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolic antagonist
US9346923B2 (en) 2011-09-11 2016-05-24 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer

Also Published As

Publication number Publication date
AU7575600A (en) 2001-04-17
EP1212099A2 (en) 2002-06-12
HUP0204110A3 (en) 2003-08-28
US20040180840A1 (en) 2004-09-16
CN1390143A (zh) 2003-01-08
MXPA02002712A (es) 2003-10-14
IL148558A0 (en) 2002-09-12
NZ517681A (en) 2004-01-30
CA2384645A1 (en) 2001-03-22
RU2002109595A (ru) 2003-11-27
US20040253206A1 (en) 2004-12-16
HUP0204110A2 (hu) 2003-04-28
BR0013948A (pt) 2002-05-14
KR20020059398A (ko) 2002-07-12
NO20021213D0 (no) 2002-03-12
WO2001019406A2 (en) 2001-03-22
US7119074B2 (en) 2006-10-10
US6713454B1 (en) 2004-03-30
NO20021213L (no) 2002-05-13
WO2001019406A3 (en) 2002-01-17
PL354261A1 (en) 2003-12-29
CZ2002928A3 (cs) 2002-09-11

Similar Documents

Publication Publication Date Title
JP2003509385A (ja) 両親媒性プロドラッグ
CZ2002929A3 (cs) Amfifilní proléčiva
RU2695220C2 (ru) Нацеленные конъюгаты и частицы и их составы
ES2607802T3 (es) Partículas lipidadas de glicosaminoglicano y su uso en el suministro de fármacos y genes para diagnóstico y terapia
US9132098B2 (en) Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
JP5520228B2 (ja) 水溶解度の低い治療剤のナノ粒子
JP7057278B2 (ja) Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤
CN102666533A (zh) 癌症治疗
CN103442563A (zh) 癌症治疗
Zhang et al. An ROS-sensitive tegafur-PpIX-heterodimer-loaded in situ injectable thermosensitive hydrogel for photodynamic therapy combined with chemotherapy to enhance the tegafur-based treatment of breast cancer
US20140037542A1 (en) Novel theranostic platform for targeted cancer therapy and drug delivery monitoring
EP2563337B1 (en) Carrier and targeting system comprising a siosomal composition for intracellular delivery and targeting of active substance
CN104479126B (zh) 多臂聚乙二醇硬脂酸衍生物和油酸衍生物
US20230120021A1 (en) Nanoparticles comprising drug dimers, and use thereof
US20240074974A1 (en) Methods and related compositions for the treatment of cancer
WO2018103660A1 (zh) Vap多肽及其在制备靶向诊疗肿瘤药物中的应用
KR102228272B1 (ko) 항암 상승효과를 나타내는 종양세포 특이적 자기조립 나노약물 복합체
CN113603877B (zh) 一种官能化双嵌段共聚物及其制备方法和用途
US20040038935A1 (en) Delivery of a therapeutic agent in a formulation for reduced toxicity
KR101732796B1 (ko) 당화합물(sugar chemical compound)-탁산화합물(taxane compound) 접합체를 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
US20040038916A1 (en) Delivery of a therapeutic agent in a formulation for reduced toxicity
CN1838942A (zh) 递送疏水性药物的组合物和方法
Xu et al. Tumor selective self-assembled nanomicelles of carbohydrate-epothilone B conjugate for targeted chemotherapy
Han et al. Self-assembled nanoparticles covalently consisting of doxorubicin and EDB fibronectin specific peptide for solid tumour treatment
US20160129117A1 (en) Novel Boronic Acid Compound Preparation

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060829